Prognostic biomarkers for cholangiocarcinoma and their clinical implications

References

• Shaib Y, El-Serag HB. The epidemiology of cholangiocarcinoma. Semin Liver Dis. 2004 May;24(2):115–125. PubMed PMID: 15192785
   PubMed Web of Science ®Google Scholar
• Rizvi S, Khan SA, Hallemeier CL, et al. Cholangiocarcinoma - evolving concepts and therapeutic strategies. Nat Rev Clin Oncol. 2017 Oct 10. DOI:10.1038/nrclinonc.2017.157 [ PubMed PMID: 28994423].
   PubMed Web of Science ®Google Scholar
• Sripa B, Pairojkul C. Cholangiocarcinoma: lessons from Thailand. Curr Opin Gastroenterol. 2008 May;24(3):349–356. PubMed PMID: 18408464
   PubMed Web of Science ®Google Scholar
• Banales JM, Cardinale V, Carpino G, et al. Expert consensus document: cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol. 2016 May;13(5):261–280. PubMed PMID: 27095655.
   PubMed Web of Science ®Google Scholar
• Nakeeb A, Pitt HA, Sohn TA, et al. Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors. Ann Surg. 1996 Oct;2244:463–473. discussion 473-5. PubMed PMID: 8857851
   PubMed Web of Science ®Google Scholar
• Jinawath N, Chamgramol Y, Furukawa Y, et al. Comparison of gene expression profiles between Opisthorchis viverrini and non-Opisthorchis viverrini associated human intrahepatic cholangiocarcinoma. Hepatology. 2006 Oct;44(4):1025–1038. PubMed PMID: 17006947.
   PubMed Web of Science ®Google Scholar
• Chan-On W, Nairismagi ML, Ong CK, et al. Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers. Nat Genet. 2013 Dec;45(12):1474–1478. PubMed PMID: 24185513.
   PubMed Web of Science ®Google Scholar
• Ong CK, Subimerb C, Pairojkul C, et al. Exome sequencing of liver fluke-associated cholangiocarcinoma. Nat Genet. 2012 May 06;44(6):690–693. PubMed PMID: 22561520.
   PubMed Web of Science ®Google Scholar
• Jarnagin WR, Fong Y, DeMatteo RP, et al. Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg. 2001 Oct;2344:507–517. discussion 517-9. PubMed PMID: 11573044
   PubMed Web of Science ®Google Scholar
• Kiefer MV, Albert M, McNally M, et al. Chemoembolization of intrahepatic cholangiocarcinoma with cisplatinum, doxorubicin, mitomycin C, ethiodol, and polyvinyl alcohol: a 2-center study. Cancer. 2011 Apr 01;117(7):1498–1505. PubMed PMID: 21425151.
   PubMed Web of Science ®Google Scholar
• Vogl TJ, Naguib NN, Nour-Eldin NE, et al. Transarterial chemoembolization in the treatment of patients with unresectable cholangiocarcinoma: results and prognostic factors governing treatment success. Int J Cancer. 2012 Aug 01;131(3):733–740. PubMed PMID: 21976289.
   PubMed Web of Science ®Google Scholar
• Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010 Apr 08;362(14):1273–1281. PubMed PMID: 20375404.
   PubMed Web of Science ®Google Scholar
• Bang YJ, Doi T, Braud FD, et al. 525 Safety and efficacy of pembrolizumab (MK-3475) in patients (pts) with advanced biliary tract cancer: interim results of KEYNOTE-028. Eur J Cancer. 2015; 51. S112. DOI:10.1016/S0959-8049(16)30326-4
   PubMed Web of Science ®Google Scholar
• Huang DW, Huang M, Lin XS, et al. CD155 expression and its correlation with clinicopathologic characteristics, angiogenesis, and prognosis in human cholangiocarcinoma. Onco Targets Ther. 2017;10:3817–3825. . PubMed PMID: 28814880.
   PubMed Web of Science ®Google Scholar
• Kunlabut K, Vaeteewoottacharn K, Wongkham C, et al. Aberrant expression of CD44 in bile duct cancer correlates with poor prognosis. Asian Pac J Cancer Prev. 2012;13(Suppl):95–99. PubMed PMID: 23480770.
   PubMedGoogle Scholar
• Thanee M, Loilome W, Techasen A, et al. CD44 variant-dependent redox status regulation in liver fluke-associated cholangiocarcinoma: a target for cholangiocarcinoma treatment. Cancer Sci. 2016 Jul;107(7):991–1000. PubMed PMID: 27176078.
   PubMed Web of Science ®Google Scholar
• Kaira K, Sunose Y, Oriuchi N, et al. CD98 is a promising prognostic biomarker in biliary tract cancer. Hepatobiliary Pancreat Dis Int. 2014 Dec;13(6):654–657. PubMed PMID: 25475870.
   PubMed Web of Science ®Google Scholar
• Meng ZW, Liu MC, Hong HJ, et al. Expression and prognostic value of soluble CD97 and its ligand CD55 in intrahepatic cholangiocarcinoma. Tumour Biol. 2017 Mar;39(3). PubMed PMID: 28345461. DOI:10.1177/1010428317694319
   Google Scholar
• Mao ZY, Zhu GQ, Ren L, et al. Prognostic value of C-met expression in cholangiocarcinoma. Technol Cancer Res Treat. 2016 Apr;15(2):227–233. PubMed PMID: 25873560.
   PubMed Web of Science ®Google Scholar
• Xu YF, Yang XQ, Lu XF, et al. Fibroblast growth factor receptor 4 promotes progression and correlates to poor prognosis in cholangiocarcinoma. Biochem Biophys Res Commun. 2014 Mar 28;446(1):54–60. PubMed PMID: 24565842.
   PubMed Web of Science ®Google Scholar
• Khansaard W, Techasen A, Namwat N, et al. Increased EphB2 expression predicts cholangiocarcinoma metastasis. Tumour Biol. 2014 Oct;35(10):10031–10041. PubMed PMID: 25012246.
   PubMedGoogle Scholar
• Zarogoulidis P, Yarmus L, Darwiche K, et al. Interleukin-6 cytokine: a multifunctional glycoprotein for cancer. Immunome Res. 2013 Aug 12;9(62):16535. PubMed PMID: 24078831.
   PubMedGoogle Scholar
• Asukai K, Kawamoto K, Eguchi H, et al. Prognostic impact of peritumoral IL-17-positive cells and IL-17 axis in patients with intrahepatic cholangiocarcinoma. Ann Surg Oncol. 2015 Dec;22(Suppl 3):S1524–S1531. PubMed PMID: 26228109.
   PubMedGoogle Scholar
• Wang Y, Wan M, Zhou Q, et al. The prognostic role of SOCS3 and A20 in human cholangiocarcinoma. PLoS One. 2015;10(10):e0141165. . PubMed PMID: 26485275.
   PubMed Web of Science ®Google Scholar
• Niu L, Qin HZ, Xi HQ, et al. RNF43 inhibits cancer cell proliferation and could be a potential prognostic factor for human gastric carcinoma. Cell Physiol Biochem. 2015;36(5):1835–1846. . PubMed PMID: 26184844.
   PubMed Web of Science ®Google Scholar
• Talabnin C, Janthavon P, Thongsom S, et al. Ring finger protein 43 expression is associated with genetic alteration status and poor prognosis among patients with intrahepatic cholangiocarcinoma. Hum Pathol. 2016 Jun;52:47–54. PubMed PMID: 26980022
   PubMed Web of Science ®Google Scholar
• Tiwari N, Tiwari VK, Waldmeier L, et al. Sox4 is a master regulator of epithelial-mesenchymal transition by controlling Ezh2 expression and epigenetic reprogramming. Cancer Cell. 2013 Jun 10;23(6):768–783. . PubMed PMID: 23764001.
   PubMed Web of Science ®Google Scholar
• Chen J, Ju HL, Yuan XY, et al. SOX4 is a potential prognostic factor in human cancers: a systematic review and meta-analysis. Clin Transl Oncol. 2016 Jan;18(1):65–72. PubMed PMID: 26250764.
   PubMed Web of Science ®Google Scholar
• Wang W, Zhang J, Zhan X, et al. SOX4 is associated with poor prognosis in cholangiocarcinoma. Biochem Biophys Res Commun. 2014 Sep 26;452(3):614–621. PubMed PMID: 25181339.
   PubMed Web of Science ®Google Scholar
• Rahnemai-Azar AA, Weisbrod A, Dillhoff M, et al. Intrahepatic cholangiocarcinoma: molecular markers for diagnosis and prognosis. Surg Oncol. 2017 Jun;26(2):125–137. PubMed PMID: 28577718.
   PubMed Web of Science ®Google Scholar
• Boonla C, Sripa B, Thuwajit P, et al. MUC1 and MUC5AC mucin expression in liver fluke-associated intrahepatic cholangiocarcinoma. World J Gastroenterol. 2005 Aug 28;11(32):4939–4946. PubMed PMID: 16124042.
   PubMed Web of Science ®Google Scholar
• Boonla C, Wongkham S, Sheehan JK, et al. Prognostic value of serum MUC5AC mucin in patients with cholangiocarcinoma. Cancer. 2003 Oct 01;98(7):1438–1443. PubMed PMID: 14508831.
   PubMed Web of Science ®Google Scholar
• Abe T, Amano H, Shimamoto F, et al. Prognostic evaluation of mucin-5AC expression in intrahepatic cholangiocarcinoma, mass-forming type, following hepatectomy. Eur J Surg Oncol. 2015 Nov;41(11):1515–1521. PubMed PMID: 26210654.
   PubMed Web of Science ®Google Scholar
• Li B, Tang H, Zhang A, et al. Prognostic role of mucin antigen MUC4 for Cholangiocarcinoma: a meta-analysis. PLoS One. 2016;11(6):e0157878. . PubMed PMID: 27305093.
   PubMed Web of Science ®Google Scholar
• Sulpice L, Rayar M, Turlin B, et al. Epithelial cell adhesion molecule is a prognosis marker for intrahepatic cholangiocarcinoma. J Surg Res. 2014 Nov;192(1):117–123. PubMed PMID: 24909871.
   PubMed Web of Science ®Google Scholar
• Bergeat D, Fautrel A, Turlin B, et al. Impact of stroma LOXL2 overexpression on the prognosis of intrahepatic cholangiocarcinoma. J Surg Res. 2016 Jun 15;203(2):441–450. PubMed PMID: 27363654.
   PubMed Web of Science ®Google Scholar
• Jamnongkan W, Thanan R, Techasen A, et al. Upregulation of transferrin receptor-1 induces cholangiocarcinoma progression via induction of labile iron pool. Tumour Biol. 2017 Jul;39(7). PubMed PMID: 28671021. DOI:10.1177/1010428317717655
   PubMedGoogle Scholar
• Morishita A, Zaidi MR, Mitoro A, et al. HMGA2 is a driver of tumor metastasis. Cancer Res. 2013 Jul 15;73(14):4289–4299. PubMed PMID: 23722545.
   PubMed Web of Science ®Google Scholar
• Lee CT, Wu TT, Lohse CM, et al. High-mobility group AT-hook 2: an independent marker of poor prognosis in intrahepatic cholangiocarcinoma. Hum Pathol. 2014 Nov;45(11):2334–2340. PubMed PMID: 25245603.
   PubMed Web of Science ®Google Scholar
• Traenka C, Remke M, Korshunov A, et al. Role of LIM and SH3 protein 1 (LASP1) in the metastatic dissemination of medulloblastoma. Cancer Res. 2010 Oct 15;70(20):8003–8014. PubMed PMID: 20924110.
   PubMed Web of Science ®Google Scholar
• Zhang H, Li Z, Chu B, et al. Upregulated LASP-1 correlates with a malignant phenotype and its potential therapeutic role in human cholangiocarcinoma. Tumour Biol. 2016 Jun;37(6):8305–8315. PubMed PMID: 26729195.
   PubMedGoogle Scholar
• Zhao X, Guo F, Li Z, et al. Aberrant expression of B7-H4 correlates with poor prognosis and suppresses tumor-infiltration of CD8+ T lymphocytes in human cholangiocarcinoma. Oncol Rep. 2016 Jul;36(1):419–427. PubMed PMID: 27177355.
   PubMed Web of Science ®Google Scholar
• Guo S, Liu HD, Liu YF, et al. Hepatoma-derived growth factor: a novel prognostic biomarker in intrahepatic cholangiocarcinoma. Tumour Biol. 2015 Jan;36(1):353–364. PubMed PMID: 25262276.
   PubMedGoogle Scholar
• Qin X, Jiang B, Zhang Y. 4E-BP1, a multifactor regulated multifunctional protein. Cell Cycle. 2016;15(6):781–786. PubMed PMID: 26901143
   PubMed Web of Science ®Google Scholar
• Fang Z, Lu L, Tian Z, et al. Overexpression of phosphorylated 4E-binding protein 1 predicts lymph node metastasis and poor prognosis of Chinese patients with hilar cholangiocarcinoma. Med Oncol. 2014 May;31(5):940. PubMed PMID: 24706262.
   PubMed Web of Science ®Google Scholar
• Zhao W, Zhang B, Guo X, et al. Expression of Ki-67, Bax and p73 in patients with hilar cholangiocarcinoma. Cancer Biomark. 2014;14(4):197–202. . PubMed PMID: 24934361.
   PubMed Web of Science ®Google Scholar
• Watanabe H, Yokoyama Y, Kokuryo T, et al. Prognostic value of hepatocyte growth factor receptor expression in patients with perihilar cholangiocarcinoma. Ann Surg Oncol. 2015 Jul;22(7):2235–2242. PubMed PMID: 25586241.
   PubMed Web of Science ®Google Scholar
• Matsushima H, Kuroki T, Kitasato A, et al. Sox9 expression in carcinogenesis and its clinical significance in intrahepatic cholangiocarcinoma. Dig Liver Dis. 2015 Dec;47(12):1067–1075. PubMed PMID: 26341967.
   PubMedGoogle Scholar
• Tongtawee T, Kaewpitoon SJ, Loyd R, et al. high expression of matrix metalloproteinase-11 indicates poor prognosis in human cholangiocarcinoma. Asian Pac J Cancer Prev. 2015;16(9):3697–3701. PubMed PMID: 25987024.
   PubMedGoogle Scholar
• Sun Q, Zhao C, Xia L, et al. High expression of matrix metalloproteinase-9 indicates poor prognosis in human hilar cholangiocarcinoma. Int J Clin Exp Pathol. 2014;7(9):6157–6164. PubMed PMID: 25337264.
   PubMed Web of Science ®Google Scholar
• Sun Q, Li F, Sun F, et al. Interleukin-8 is a prognostic indicator in human hilar cholangiocarcinoma. Int J Clin Exp Pathol. 2015;8(7):8376–8384. PubMed PMID: 26339407.
   PubMed Web of Science ®Google Scholar
• Lv L, Wei M, Lin P, et al. Integrated mRNA and lncRNA expression profiling for exploring metastatic biomarkers of human intrahepatic cholangiocarcinoma. Am J Cancer Res. 2017;7(3):688–699. PubMed PMID: 28401021.
   PubMed Web of Science ®Google Scholar
• Xu Y, Wang Z, Jiang X, et al. Overexpression of long noncoding RNA H19 indicates a poor prognosis for cholangiocarcinoma and promotes cell migration and invasion by affecting epithelial-mesenchymal transition. Biomed Pharmacother. 2017 Aug;92:17–23. PubMed PMID: 28528181
   PubMed Web of Science ®Google Scholar
• Xu Y, Jiang X, Cui Y. Upregulated long noncoding RNA PANDAR predicts an unfavorable prognosis and promotes tumorigenesis in cholangiocarcinoma. Onco Targets Ther. 2017;10:2873–2883. . PubMed PMID: 28652769.
   PubMed Web of Science ®Google Scholar
• Lan H, Lu H, Wang X, et al. MicroRNAs as potential biomarkers in cancer: opportunities and challenges. Biomed Res Int. 2015;2015:125094. . PubMed PMID: 25874201.
   PubMed Web of Science ®Google Scholar
• Zhang MY, Li SH, Huang GL, et al. Identification of a novel microRNA signature associated with intrahepatic cholangiocarcinoma (ICC) patient prognosis. BMC Cancer. 2015 Feb;18(15):64. PubMed PMID: 25880914.
   PubMed Web of Science ®Google Scholar
• Severino FE, Hashimoto CN, Rodringues MA, et al. Integrative analysis of transcriptome and microRNome profiles in cholangiocarcinoma. J Can Sci Ther. 2017 Aug;9(8):580–588.
   Google Scholar
• Yokomine K, Senju S, Nakatsura T, et al. The forkhead box M1 transcription factor as a candidate of target for anti-cancer immunotherapy. Int J Cancer. 2010 May 1;126(9):2153–2163. PubMed PMID: 19688828.
   PubMed Web of Science ®Google Scholar
• Jiang H, Zhang G, Wu JH, et al. Diverse roles of miR-29 in cancer (review). Oncol Rep. 2014 Apr;31(4):1509–1516. PubMed PMID: 24573597.
   PubMed Web of Science ®Google Scholar
• Deng Y, Chen Y. Increased Expression of miR-29a and Its Prognostic Significance in Patients with Cholangiocarcinoma. Oncol Res Treat. 2017;40(3):128–132. PubMed PMID: 28118648
   PubMed Web of Science ®Google Scholar
• Thom I, Andritzky B, Schuch G, et al. Elevated pretreatment serum concentration of YKL-40-an independent prognostic biomarker for poor survival in patients with metastatic nonsmall cell lung cancer. Cancer. 2010 Sep 1;116(17):4114–4121. PubMed PMID: 20564116.
   PubMed Web of Science ®Google Scholar
• Francescone RA, Scully S, Faibish M, et al. Role of YKL-40 in the angiogenesis, radioresistance, and progression of glioblastoma. J Biol Chem. 2011 Apr 29;286(17):15332–15343. PubMed PMID: 21385870.
   PubMed Web of Science ®Google Scholar
• Thongsom S, Chaocharoen W, Silsirivanit A, et al. YKL-40/chitinase-3-like protein 1 is associated with poor prognosis and promotes cell growth and migration of cholangiocarcinoma. Tumour Biol. 2016 Jul;37(7):9451–9463. PubMed PMID: 26781979.
   PubMedGoogle Scholar
• Silsirivanit A, Araki N, Wongkham C, et al. CA-S27: a novel Lewis a associated carbohydrate epitope is diagnostic and prognostic for cholangiocarcinoma. Cancer Sci. 2013 Oct;104(10):1278–1284. . PubMed PMID: 23809433.
   PubMed Web of Science ®Google Scholar
• Thuwajit C, Thuwajit P, Jamjantra P, et al. Clustering of patients with intrahepatic cholangiocarcinoma based on serum periostin may be predictive of prognosis. Oncol Lett. 2017 Jul;14(1):623–634. PubMed PMID: 28693214.
   PubMed Web of Science ®Google Scholar
• Utispan K, Thuwajit P, Abiko Y, et al. Gene expression profiling of cholangiocarcinoma-derived fibroblast reveals alterations related to tumor progression and indicates periostin as a poor prognostic marker. Mol Cancer. 2010 Jan;24(9):13. PubMed PMID: 20096135.
   PubMed Web of Science ®Google Scholar
• Yoh T, Seo S, Hatano E, et al. A novel biomarker-based preoperative prognostic grading system for predicting survival after surgery for intrahepatic cholangiocarcinoma. Ann Surg Oncol. 2017 May;24(5):1351–1357. PubMed PMID: 28108828.
   PubMed Web of Science ®Google Scholar
• Lin ZY, Liang ZX, Zhuang PL, et al. Intrahepatic cholangiocarcinoma prognostic determination using pre-operative serum C-reactive protein levels. BMC Cancer. 2016 Oct 12;16(1):792. PubMed PMID: 27733196.
   PubMedGoogle Scholar
• Loosen SH, Roderburg C, Kauertz KL, et al. Elevated levels of circulating osteopontin are associated with a poor survival after resection of cholangiocarcinoma. . J Hepatol. 2017 Oct;67(4):749–757. . PubMed PMID: 268580.
   PubMed Web of Science ®Google Scholar
• Wu H, Zhang H, Hu L-Y, et al. Is osteopontin a promising prognostic biomarker for cholangiocarcinoma? J Hepatol. 2017. DOI:10.1016/j.jhep.2017.08.029
   Web of Science ®Google Scholar
• Tolek A, Wongkham C, Proungvitaya S, et al. Serum alpha1beta-glycoprotein and afamin ratio as potential diagnostic and prognostic markers in cholangiocarcinoma. Exp Biol Med (Maywood). 2012 Oct;237(10):1142–1149. . PubMed PMID: 23104505.
   PubMed Web of Science ®Google Scholar
• Jing CY, Fu YP, Shen HJ, et al. Albumin to gamma-glutamyltransferase ratio as a prognostic indicator in intrahepatic cholangiocarcinoma after curative resection. Oncotarget. 2017 Feb 21;8(8):13293–13303. PubMed PMID: 28076328.
   PubMedGoogle Scholar
• Liu L, Wang W, Zhang Y, et al. Declined preoperative aspartate aminotransferase to neutrophil ratio index predicts poor prognosis in patients with intrahepatic cholangiocarcinoma after hepatectomy. Cancer Res Treat. 2017 Jun 01. DOI:10.4143/crt.2017.106 [ PubMed PMID: 28602056].
   Google Scholar
• Wang LJ, Zhang KL, Zhang N, et al. Serum miR-26a as a diagnostic and prognostic biomarker in cholangiocarcinoma. Oncotarget. 2015 Jul 30;6(21):18631–18640. PubMed PMID: 26087181.
   PubMedGoogle Scholar
• Hao XY, Cai JP, Liu X, et al. EYA4 gene functions as a prognostic marker and inhibits the growth of intrahepatic cholangiocarcinoma. Chin J Cancer. 2016 Jul 28;35(1):70. PubMed PMID: 27469137.
   PubMedGoogle Scholar
• Ho L, Crabtree GR. Chromatin remodelling during development. Nature. 2010 Jan 28;463(7280):474–484. PubMed PMID: 20110991.
   PubMed Web of Science ®Google Scholar
• Luchini C, Veronese N, Solmi M, et al. Prognostic role and implications of mutation status of tumor suppressor gene ARID1A in cancer: a systematic review and meta-analysis. Oncotarget. 2015 Nov 17;6(36):39088–39097. PubMed PMID: 26384299.
   PubMedGoogle Scholar
• Yang SZ, Wang AQ, Du J, et al. Low expression of ARID1A correlates with poor prognosis in intrahepatic cholangiocarcinoma. World J Gastroenterol. 2016 Jul 07;22(25):5814–5821. PubMed PMID: 27433094.
   PubMed Web of Science ®Google Scholar
• Xie F, Ye L, Ta M, et al. MTSS1: a multifunctional protein and its role in cancer invasion and metastasis. Front Biosci (Schol Ed). 2011 1;Jan(3):621–631. PubMed PMID: 21196400.
   Google Scholar
• Shi W, Hasimu G, Wang Y, et al. MTSS1 is an independent prognostic biomarker for survival in intrahepatic cholangiocarcinoma patients. Am J Transl Res. 2015;7(10):1974–1983. PubMed PMID: 26692940.
   PubMed Web of Science ®Google Scholar
• Vincent KM, Postovit LM. A pan-cancer analysis of secreted Frizzled-related proteins: re-examining their proposed tumour suppressive function. Sci Rep. 2017 Feb 20;7:42719. PubMed PMID: 28218291.
   PubMed Web of Science ®Google Scholar
• Davaadorj M, Saito Y, Morine Y, et al. Loss of Secreted frizzled-related protein-1 expression is associated with poor prognosis in intrahepatic cholangiocarcinoma. Eur J Surg Oncol. 2017 Feb;43(2):344–350. PubMed PMID: 28062160.
   PubMed Web of Science ®Google Scholar
• de Kruijf EM, Sajet A, VAn Nes JG, et al. NKG2D ligand tumor expression and association with clinical outcome in early breast cancer patients: an observational study. BMC Cancer. 2012 Jan;18(12):24. PubMed PMID: 22257486.
   PubMed Web of Science ®Google Scholar
• Zhang J, Basher F, Wu JD. NKG2D ligands in tumor immunity: two sides of a coin. Front Immunol. 2015;6:97. . PubMed PMID: 25788898.
   PubMed Web of Science ®Google Scholar
• Tsukagoshi M, Wada S, Yokobori T, et al. Overexpression of natural killer group 2 member D ligands predicts favorable prognosis in cholangiocarcinoma. Cancer Sci. 2016 Feb;107(2):116–122. PubMed PMID: 26608587.
   PubMed Web of Science ®Google Scholar
• Thanee M, Loilome W, Techasen A, et al. Quantitative changes in tumor-associated M2 macrophages characterize cholangiocarcinoma and their association with metastasis. Asian Pac J Cancer Prev. 2015;16(7):3043–3050. PubMed PMID: 25854403.
   PubMedGoogle Scholar
• Atanasov G, Hau HM, Dietel C, et al. Prognostic significance of macrophage invasion in hilar cholangiocarcinoma. BMC Cancer. 2015 Oct;24(15):790. PubMed PMID: 26497197.
   PubMed Web of Science ®Google Scholar
• Subimerb C, Pinlaor S, Lulitanond V, et al. Circulating CD14(+) CD16(+) monocyte levels predict tissue invasive character of cholangiocarcinoma. Clin Exp Immunol. 2010 Sep;161(3):471–479. PubMed PMID: 20636398.
   PubMed Web of Science ®Google Scholar
• Subimerb C, Wongkham C, Khuntikeo N, et al. Transcriptional profiles of peripheral blood leukocytes identify patients with cholangiocarcinoma and predict outcome. Asian Pac J Cancer Prev. 2014;15(10):4217–4224. PubMed PMID: 24935374.
   PubMedGoogle Scholar
• Faria SS, Fernandes PC Jr., Silva MJ, et al. The neutrophil-to-lymphocyte ratio: a narrative review. Ecancermedicalscience. 2016;10:702. . PubMed PMID: 28105073.
   PubMed Web of Science ®Google Scholar
• Templeton AJ, McNamara MG, Seruga B, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst. 2014 Jun;106(6):dju124. PubMed PMID: 24875653.
   PubMedGoogle Scholar
• Omichi K, Cloyd JM, Yamashita S, et al. Neutrophil-to-lymphocyte ratio predicts prognosis after neoadjuvant chemotherapy and resection of intrahepatic cholangiocarcinoma. Surgery. 2017 Oct;162(4):752–765. PubMed PMID: 28688518.
   PubMed Web of Science ®Google Scholar
• Lin G, Liu Y, Li S, et al. Elevated neutrophil-to-lymphocyte ratio is an independent poor prognostic factor in patients with intrahepatic cholangiocarcinoma. Oncotarget. 2016 Aug 09;7(32):50963–50971. PubMed PMID: 26918355.
   PubMedGoogle Scholar
• Tan DW, Fu Y, Su Q, et al. Prognostic significance of neutrophil to lymphocyte ratio in oncologic outcomes of cholangiocarcinoma: a meta-analysis. Sci Rep. 2016 Oct 03; 6:33789. PubMed PMID: 27694951.
   PubMed Web of Science ®Google Scholar
• Holohan C, Van Schaeybroeck S, Longley DB, et al. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer. 2013 Oct;13(10):714–726. PubMed PMID: 24060863.
   PubMed Web of Science ®Google Scholar
• Housman G, Byler S, Heerboth S, et al. Drug resistance in cancer: an overview. Cancers (Basel). 2014 Sep 5;6(3):1769–1792. PubMed PMID: 25198391.
   PubMed Web of Science ®Google Scholar
• Herraez E, Lozano E, Macias RI, et al. Expression of SLC22A1 variants may affect the response of hepatocellular carcinoma and cholangiocarcinoma to sorafenib. Hepatology. 2013 Sep;58(3):1065–1073. PubMed PMID: 23532667.
   PubMed Web of Science ®Google Scholar
• Srimunta U, Sawanyawisuth K, Kraiklang R, et al. High expression of ABCC1 indicates poor prognosis in intrahepatic cholangiocarcinoma. Asian Pac J Cancer Prev. 2012;13(Suppl):125–130. PubMed PMID: 23480753.
   PubMedGoogle Scholar
• Rau S, Autschbach F, Riedel HD, et al. Expression of the multidrug resistance proteins MRP2 and MRP3 in human cholangiocellular carcinomas. Eur J Clin Invest. 2008 Feb;38(2):134–142. PubMed PMID: 18226047.
   PubMed Web of Science ®Google Scholar
• Sribenja S, Wongkham S, Wongkham C, et al. Roles and mechanisms of beta-thymosins in cell migration and cancer metastasis: an update. Cancer Invest. 2013 Feb;31(2):103–110. PubMed PMID: 23320791.
   PubMed Web of Science ®Google Scholar
• Sribenja S, Natthasirikul N, Vaeteewoottacharn K, et al. Thymosin beta10 as a predictive biomarker of response to 5-fluorouracil chemotherapy in cholangiocarcinoma. Ann Hepatol. 2016 Jul-Aug;15(4):577–585. PubMed PMID: 27236157.
   PubMed Web of Science ®Google Scholar
• Yoon H, Min JK, Lee JW, et al. Acquisition of chemoresistance in intrahepatic cholangiocarcinoma cells by activation of AKT and extracellular signal-regulated kinase (ERK)1/2. Biochem Biophys Res Commun. 2011 Feb 18;405(3):333–337. PubMed PMID: 21130731.
   PubMed Web of Science ®Google Scholar
• Nutthasirikul N, Hahnvajanawong C, Techasen A, et al. Targeting the 133p53 isoform can restore chemosensitivity in 5-fluorouracil-resistant cholangiocarcinoma cells. Int J Oncol. 2015 Dec;47(6):2153–2164. PubMed PMID: 26459801.
   PubMed Web of Science ®Google Scholar
• Brivio S, Cadamuro M, Fabris L, et al. Epithelial-to-mesenchymal transition and cancer invasiveness: what can we learn from cholangiocarcinoma? J Clin Med. 2015 Dec 19;4(12):2028–2041. PubMed PMID: 26703747.
   PubMed Web of Science ®Google Scholar
• Chiang KC, Yeh TS, Wu RC, et al. Lipocalin 2 (LCN2) is a promising target for cholangiocarcinoma treatment and bile LCN2 level is a potential cholangiocarcinoma diagnostic marker. Sci Rep. 2016 Oct;26(6):36138. PubMed PMID: 27782193.
   PubMed Web of Science ®Google Scholar
• Marin JJG, Lozano E, Herraez E, et al. Chemoresistance and chemosensitization in cholangiocarcinoma. Biochim Biophys Acta. 2017 Jul 07. DOI:10.1016/j.bbadis.2017.06.005 [ PubMed PMID: 28600147].
   Web of Science ®Google Scholar
• Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012 Mar 22;12(4):252–264. PubMed PMID: 22437870.
   PubMed Web of Science ®Google Scholar
• Fontugne J, Augustin J, Pujals A, et al. PD-L1 expression in perihilar and intrahepatic cholangiocarcinoma. Oncotarget. 2017 Apr 11;8(15):24644–24651. PubMed PMID: 28445951.
   PubMedGoogle Scholar
• Walter D, Herrmann E, Schnitzbauer AA, et al. PD-L1 expression in extrahepatic cholangiocarcinoma. Histopathology. 2017 Sep;71(3):383–392. PubMed PMID: 28419539.
   PubMed Web of Science ®Google Scholar
• Gani F, Nagarajan N, Kim Y, et al. Program death 1 immune checkpoint and tumor microenvironment: implications for patients with intrahepatic cholangiocarcinoma. Ann Surg Oncol. 2016 Aug;23(8):2610–2617. PubMed PMID: 27012989.
   PubMed Web of Science ®Google Scholar
• Silsirivanit A, Sawanyawisufth K, Riggins GJ, et al. Cancer biomarker discovery for cholangiocarcinoma: the high-throughput approaches. J Hepatobiliary Pancreat Sci. 2014 Jun;21(6):388–396. PubMed PMID: 24616382.
   PubMed Web of Science ®Google Scholar
• Macias RIR, Banales JM, Sangro B, et al. The search for novel diagnostic and prognostic biomarkers in cholangiocarcinoma. Biochim Biophys Acta. 2018 Apr;1864(4 Pt B):1468–1477. PubMed PMID: 28782657.
   PubMed Web of Science ®Google Scholar
• Kondo N, Murakami Y, Uemura K, et al. Elevated perioperative serum CA 19-9 levels are independent predictors of poor survival in patients with resectable cholangiocarcinoma. J Surg Oncol. 2014 Sep;110(4):422–429. PubMed PMID: 24889968.
   PubMed Web of Science ®Google Scholar
• Liang B, Zhong L, He Q, et al. Diagnostic accuracy of serum CA19-9 in patients with cholangiocarcinoma: a systematic review and meta-analysis. Med Sci Monit. 2015 Nov;18(21):3555–3563. PubMed PMID: 26576628.
   Google Scholar
• Coelho R, Silva M, Rodrigues-Pinto E, et al. CA 19-9 as a marker of survival and a predictor of metastization in cholangiocarcinoma. GE Port J Gastroenterol. 2017 May;24(3):114–121. PubMed PMID: 28848795.
   Google Scholar
• Bergquist JR, Ivanics T, Storlie CB, et al. Implications of CA19-9 elevation for survival, staging, and treatment sequencing in intrahepatic cholangiocarcinoma: a national cohort analysis. J Surg Oncol. 2016 Sep;114(4):475–482. PubMed PMID: 27439662.
   PubMed Web of Science ®Google Scholar